CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

Rhea-AI Summary

Cyclacel Pharmaceuticals (NASDAQ: CYCC) has announced a 1-for-16 reverse stock split effective May 12, 2025. The company's common stock will continue trading on the Nasdaq Capital Market under the symbol "CYCC" with a new CUSIP number 23254L884.

Following the split, every 16 shares will automatically convert into one share, with fractional shares being rounded up or down. The pre-split share count of 356,357,531 will be reduced to 22,272,346 post-split. The reverse split was approved by both the board of directors and stockholders, and will not alter shareholders' percentage ownership in the company, except for minor adjustments due to fractional shares.

Positive

• None.

Negative

• Implementing a reverse stock split typically indicates share price concerns and potential Nasdaq listing compliance issues
• The 1-for-16 ratio represents a significant share consolidation that could impact stock liquidity

Insights

Financial Analyst

Cyclacel's 1-for-16 reverse split will mechanically reduce shares while maintaining relative ownership percentages, typically done to boost share price.

Cyclacel Pharmaceuticals has announced a significant 1-for-16 reverse stock split effective May 12, 2025. This corporate action will consolidate the company's outstanding shares from 356,357,531 to approximately 22,272,346 shares while maintaining each shareholder's proportional ownership percentage in the company.

This reverse split represents a substantial consolidation ratio that exceeds typical reverse splits often seen at 1-for-5 or 1-for-10. While the press release doesn't specify the motivation, reverse splits are commonly implemented to raise the per-share trading price. The mathematical effect is straightforward: fewer shares outstanding with each share representing a larger ownership stake.

From a practical standpoint, shareholders will automatically have their holdings adjusted in their brokerage accounts. Those with share counts not divisible by 16 should note that fractional shares will be rounded up or down to the nearest whole number, which could result in minor adjustments to overall positions for some investors.

The company has completed all necessary governance steps with approval from both the board of directors and stockholders. Trading will continue uninterrupted under the same "CYCC" ticker symbol, though with a new CUSIP number (23254L884), which serves as the security's identifying number for settlement purposes.

While reverse splits don't fundamentally change a company's market capitalization or enterprise value, they do represent significant structural changes to how ownership is denominated and shares are traded.

BERKELEY HEIGHTS, NJ, May 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it expects to implement a 1-for-16 reverse stock split on its shares of common stock effective May 12, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the shares of common stock will continue on The Nasdaq Capital Market under the symbol “CYCC”. The new CUSIP number for the shares of common stock following the reverse stock split is 23254L884.

Upon the effectiveness of the reverse stock split, every 16 shares of the Company’s issued and outstanding shares of common stock will automatically convert into one issued and outstanding share of common stock. No fractional shares will be issued as a result of the reverse stock split. Instead, any fractional shares that would have resulted from the split will be rounded up or down to the next whole number, as applicable. The reverse stock split affects all shareholders uniformly and will not alter any shareholder’s percentage interest in the Company’s outstanding shares of common stock, except for adjustments that may result from the treatment of fractional shares.

The reverse stock split at a ratio of 1-for-16 shares was approved by the Company’s board of directors and its stockholders. The Company will file a Certificate of Amendment with the Secretary of State of the State of Delaware to reflect the reverse stock split occurring on May 12, 2025. The pre-reverse stock split number of shares of common stock issued and outstanding is 356,357,531 and the post-reverse stock split number of common stock issued and outstanding will be 22,272,346. 

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, epigenetics and mitosis biology. The epigenetic/anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel’s strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com. 

Forward-looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, Cyclacel’s future plans and prospects, Cyclacel’s anticipated cash runway and the planned timing of data results and continued development of plogosertib. Factors that may cause actual results to differ materially include market and other conditions, the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates and Cyclacel’s ability to regain and maintain compliance with Nasdaq’s continued listing requirements, although no assurance to that effect can be given. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Cyclacel Pharmaceuticals, Inc.
Datuk Dr. Doris Wong Sing Ee
Chief Executive Officer
Email: ir@cyclacel.com

© Copyright 2025 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel^® are trademarks of Cyclacel Pharmaceuticals, Inc.

SOURCE:
Cyclacel Pharmaceuticals, Inc.

FAQ

What is the reverse stock split ratio for Cyclacel Pharmaceuticals (CYCC) and when is it effective?

Cyclacel Pharmaceuticals (CYCC) will implement a 1-for-16 reverse stock split effective May 12, 2025, with trading to begin on a split-adjusted basis at market open.

How many CYCC shares will be outstanding after the reverse stock split?

After the 1-for-16 reverse stock split, Cyclacel's outstanding shares will decrease from 356,357,531 to 22,272,346 shares.

Will CYCC shareholders receive fractional shares in the reverse split?

No, fractional shares resulting from the reverse split will be rounded up or down to the next whole number.

Will the Cyclacel reverse stock split affect shareholders' ownership percentage?

No, the reverse split will not alter shareholders' percentage interest in the company, except for minor adjustments from fractional share rounding.

What is CYCC's new CUSIP number after the reverse stock split?

Cyclacel's new CUSIP number following the reverse stock split is 23254L884.